AstraZeneca pays up to $1bn for biotech firm that could transform cell therapy'AstraZeneca's $1bn acquisition of EsoBiotec aims to enhance access to rapid cell therapies for cancer treatment.
Breakthrough therapies at Stanford are saving lives. Can we afford them?Cell and gene therapies offer promising medical solutions but come with a hefty price tag, raising concerns about availability and affordability.
Swiss startup creates modular device for on-demand cell therapy manufacturingAutomated cell therapy manufacturing with less stress and contamination through modular device.
Breakthrough therapies at Stanford are saving lives. Can we afford them?Cell and gene therapies offer promising medical solutions but come with a hefty price tag, raising concerns about availability and affordability.
Swiss startup creates modular device for on-demand cell therapy manufacturingAutomated cell therapy manufacturing with less stress and contamination through modular device.